A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LB4330 in Patients With Advanced Solid Tumors（MEETCD8-001）

NCT05707676 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class

Stopped Due to adjustments in the sponsor's development strategy, it has been decided to terminate the study.

Conditions

Interventions

Sponsor

L & L Bio Co., Ltd., Ningbo, China